KNSA

93.6500.12%
ET

Eben Tessari

Consultant

Mr. Eben Tessari serves as Consultant of Kiniksa Pharmaceuticals International, plc since May 15, 2026. At Kiniksa Pharmaceuticals International, plc, he also served as Executive VP & Chief Strategy Officer from January 2026 to May 15, 2026, as Chief Strategy Officer from January 10, 2026 to May 15, 2026, as Executive VP & COO from January 2025 to January 10, 2026, as Senior VP & COO from January 3, 2022 to December 2024, as Senior VP & Chief Business Officer from March 2018 to January 3, 2022, and as Senior Vice President of Business Development from July 2015 to March 2018. During his tenure, he oversaw the Company’s business development efforts, including the expansion of its product candidate portfolio. He joined the firm in July 2015. He serves as Entrepreneur-in-Residence of Atlas Venture Advisors, Inc. since May 2026. Prior to that, he served as Senior Director and Head of Business Development at Synageva BioPharma. Before that, he was Director, Business and Corporate Development at Civitas Therapeutics, Inc. from November 2013 to December 2014, where he played a lead role in managing the company through an acquisition by Acorda Therapeutics. Before joining Civitas, he worked in a variety of roles with increasing responsibility at Vertex Pharmaceuticals, Zalicus and EPIX Pharmaceuticals. Mr. Tessari has several years' experience in long-range strategic planning, forecasting, decision analysis, business development, licensing, valuation and new product strategy. He has a M.S. in Biomedical Engineering from Boston University, a J.D. from Suffolk University, a M.B.A. from Suffolk University, and a B.S. in Neuroscience from Northeastern University.

Positions